Vertex Pharmaceuticals’ (VRTX) “Outperform” Rating Reaffirmed at William Blair
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...
Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day
Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.
Vertex Pharmaceuticals: Strategic Advancements and Promising Pipeline Drive Buy Rating
Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...
Moderna's mRNA Technology Looks Undervalued Despite Lower Covid Vaccine Demand
Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...
Hosted on MSN4d
Vertex Pharmaceuticals (VRTX) Stock Moves -0.62%: What You Should Know
In the latest market close, Vertex Pharmaceuticals (VRTX) reached $409.56, with a -0.62% movement compared to the previous day. This change was narrower than the S&P 500's 1.54% loss on the day.
Royalty Pharma Announces Transformative Step In Company’S Evolution With Acquisition Of Its External Manager And $3 Billion Share Repurchase Program
Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLC <li /> <str ...
Le Lézard6d
Who Cares: New Podcast Explores the Hidden Realities of Caregiving in Canada
A mother leaves her career to care for her son with cerebral palsy full-time. An adult sibling spends their days navigating the complexities of caregiving for their brother with a disability. A ...